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HEART FAILURE AND IMAGING
CASE REPORT: CLINICAL CASE

Cardiac Tamponade Secondary
to COVID-19
Mohammed F. Dabbagh, MD,a Lindsey Aurora, MD,a Penny D’Souza, DO,a Allison J. Weinmann, MBBS,b
Pallavi Bhargava, MD,b Mir B. Basir, DOa

ABSTRACT
A 67-year-old woman presented with upper respiratory symptoms and was diagnosed with coronavirus disease-2019
(COVID-19). She was found to have a large hemorrhagic pericardial effusion with echocardiographic signs of tamponade
and mild left ventricular impairment. Clinical course was complicated by development of takotsubo cardiomyopathy.
She was treated with pericardiocentesis, colchicine, corticosteroids, and hydroxychloroquine, with improvement in
symptoms. (Level of Difﬁculty: Intermediate.) (J Am Coll Cardiol Case Rep 2020;2:1326–30) © 2020 The Authors.
Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

HISTORY OF PRESENTATION

Physical exam was pertinent for a blood pressure of
118/82 mm Hg, heart rate of 122 beats/min, respi-

A 67-year-old woman presented to the emergency

ratory

department with cough, mild shortness of breath, and

36.8  C, normal oxygen saturation on room air,

left shoulder pain. Physical exam and radiographic

distant heart sounds, and rales at the lung bases

imaging of the chest were unremarkable (Figure 1). A

bilaterally.

nasopharyngeal swab was positive for severe acute
respiratory syndrome-coronavirus-2 (SARS-CoV-2) by

rate

of

24

breaths/min,

temperature

of

PAST MEDICAL HISTORY

reverse transcription polymerase chain reaction. She
was discharged home due to mild symptoms.

The patient had a history of nonischemic cardiomy-

One week after her initial presentation, she

opathy with left ventricular ejection fraction (LVEF)

presented with worsening dyspnea and orthopnea.

of 15%, diagnosed in 2018 and managed with
guideline-directed medical therapy with improve-

LEARNING OBJECTIVES
 To recognize that COVID-19 can have
extrapulmonary manifestations, which can
be readily identiﬁed with physical examination and simple diagnostic studies.
 To identify COVID-19 as a potential etiology
of hemorrhagic pericardial effusion.

ment in her LVEF to 40%. She had not been not prescribed antiplatelet agents or anticoagulants and had
no history of malignancy or coagulopathy.

DIFFERENTIAL DIAGNOSIS
The differential diagnosis included evolving coronavirus disease-2019 (COVID-19) pneumonia, acute-on-

From the aHeart and Vascular Institute, Henry Ford Hospital, Detroit, Michigan; and the bDepartment of Infectious Disease, Henry
Ford Hospital, Detroit, Michigan. The authors have reported that they have no relationships relevant to the contents of this paper
to disclose.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit
the JACC: Case Reports author instructions page.
Manuscript received April 14, 2020; accepted April 16, 2020.

ISSN 2666-0849

https://doi.org/10.1016/j.jaccas.2020.04.009

Dabbagh et al.

JACC: CASE REPORTS, VOL. 2, NO. 9, 2020
JULY 15, 2020:1326–30

chronic heart failure exacerbation, acute coronary

severe

syndrome, acute pulmonary embolism, myocarditis,

she underwent elective intubation and was

and pericardial disease.

taken to the cardiac catheterization labora-

coughing

spells

and

emesis,

ABBREVIATIONS

so

AND ACRONYMS
COVID-19 = coronavirus

tory. Pericardiocentesis yielded 800 ml of

INVESTIGATIONS

exudative

Chest x-ray ﬁlm and computed tomography angiogram
obtained 1 week prior to admission were negative for
pneumonia or pulmonary embolism. Upon representation to the hospital, chest x-ray ﬁlm demonstrated an
enlarged cardiac silhouette and electrocardiography
(ECG) revealed low voltage in the limb leads with
nonspeciﬁc ST-segment changes (Figure 2). Laboratory
testing demonstrated normal levels of high-sensitivity
cardiac troponin I (cTnI) (<18 ng/l; reference range
[RR]: <19 ng/l) and mildly elevated brain natriuretic
peptide (54 pg/ml; RR: <50 pg/ml). Transthoracic
echocardiography (TTE) (Videos 1 and 2) revealed a
large pericardial effusion circumferentially around the
entire heart with signs of early right ventricular diastolic collapse, dilated but collapsing inferior vena
cava, and mitral valve inﬂow variation of 31% on
pulsed wave Doppler. LVEF was mildly reduced at
40%, with no regional wall motion abnormalities,
similar to TTE 1 year prior.

ﬂuid

bloody

(ﬂuid

disease-2019

lactate

cTnI = cardiac troponin I

dehydrogenase [LDH] 1,697 IU/l, pericardial

ECG = electrocardiography

ﬂuid LDH/serum LDH >0.6). Fluid cytology

LDH = lactate dehydrogenase

was negative for malignant cells. Acid-fast

LVEF = left ventricular

bacilli smear was negative, and there was no

ejection fraction

growth on cultures. Samples of the ﬂuid

RR = reference range

were frozen in an effort to test the presence

SARS-CoV-2 = severe acute

of SARS-CoV-2, which is currently not avail-

respiratory syndrome-

able in our center. Serum autoimmune work-

coronavirus-2

up was negative. In the absence of a history

TTC = takotsubo

of malignancy, chest trauma, or coagulop-

cardiomyopathy

athy, we suspected the hemorrhagic effusion

TTE = transthoracic

to be secondary to COVID-19. Treatment was

echocardiography

started with hydroxychloroquine along with colchicine and glucocorticoids given elevated serum inﬂammatory markers: C-reactive protein (15.9 mg/dl;
RR: <0.5 mg/dl), ferritin (593 ng/ml; RR: 11 to 307 ng/
ml),

D-dimer

(6.52

mg/ml; RR: <0.68 mg/ml),

and interlukin-6 (8 pg/ml; RR: #5 pg/ml). Serial TTE
demonstrated resolution of the pericardial effusion;
however, the patient was found to have new hypo-

MANAGEMENT

kinesis

of

the

apical

and

periapical

walls

concerning for takotsubo cardiomyopathy (TTC)
Given the patient’s worsening symptoms, rapid

(Video 3). This coincided with a rise in cTnI levels to

expansion

2,410

of

the

effusion

over

1

week,

and

(ng/l)

and

deep

T-wave

inversions

in

early echocardiographic ﬁndings of tamponade, we

precordial leads (V 2 to V6 ) (Figure 3). The patient did

elected to proceed with pericardiocentesis. The pa-

not develop any chest pain or worsening dyspnea. On

tient

could

not
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tolerate

lying

ﬂat

because

of

the

contrary,

she

reported

improvement

F I G U R E 1 Imaging on Initial Presentation

Chest x-ray ﬁlm (left) and chest computed tomography (right) showing no acute lung disease. Cardiac silhouette appears normal.

of
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F I G U R E 2 Chest X-Ray Film and Electrocardiography on Second Presentation

(Left) Chest x-ray ﬁlm: enlarged cardiac silhouette. (Right) Electrocardiography: normal sinus rhythm with low-voltage QRS complex in limb leads and nonspeciﬁc STsegment changes in precordial leads.

F I G U R E 3 Electrocardiogram After Pericardiocentesis

Electrocardiography: sinus rhythm with deep T-wave inversions in precordial leads V2 to V6.

Dabbagh et al.
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dyspnea and was subsequently discharged from the

ECG abnormalities or modest cardiac troponin eleva-

hospital.

tion, and absence of pheochromocytoma or myocarditis (9). Our patient met these diagnostic criteria

DISCUSSION

clinically and echocardiogram was consistent with
apical ballooning. Cardiac magnetic resonance would

SARS-CoV-2 is the novel virus that causes COVID-19

have deﬁnitively ruled out the presence of myocar-

(1). Early studies from Wuhan, China, demonstrated

ditis. However, it was not performed, as the patient’s

that patients commonly develop fever, upper respi-

condition continued to improve, and we sought to

ratory symptoms, and pneumonia (2). As the disease

further avoid nonessential medical testing to mini-

has spread globally, reports of extrapulmonary man-

mize spread of the disease. Acute coronary syndrome

ifestations have been frequently identiﬁed; however,

was unlikely, as coronary angiography from 2 years

pericardial involvement has been rarely reported

prior

(3,4). Here, we report the case of a patient who

disease, and the patient demonstrated no symptoms

developed large symptomatic hemorrhagic pericar-

of acute coronary syndrome. Although TTC has

dial effusion causing cardiac tamponade. There were

been widely reported in the setting of severe

no initial signs of cardiac injury or myocardial

bacterial infections, cases of TTC attributed to viral

involvement, as demonstrated by the absence of cTnI

infections such as inﬂuenza are rare (10). In our case,

elevation or wall motion abnormalities on TTE. In

troponin elevation and apical hypokinesis occurred

fact, her symptoms were relatively mild until the

only after intubation and pericardiocentesis; there-

development of pericardial effusion.

fore, stress from these procedures is also a possible

Viral infections are a common cause of pericarditis
and typically entail a benign clinical course (5). Hemorrhagic

pericardial

effusions

have

been

less

commonly associated with viral infections but have
been reported in coxsackievirus (6). It is hypothesized
that viruses cause pericardial inﬂammation via direct
cytotoxic effects or via immune-mediated mechanisms (5). COVID-19 has been reported to trigger an
exaggerated

systemic

inﬂammatory

response

in

certain patients; however, details of this response are
not fully understood (3). It is plausible that COVID-19,
similar to other viral infections, elicits an inﬂammatory response, leading to pericarditis and subsequent
effusion; however, the exact mechanism is unclear.
Hemorrhagic effusions have also been reported in
other inﬂammatory states such as Dressler’s syndrome, which is thought to result from an immune
complex deposition and a subsequent inﬂammatory

showed

no

signiﬁcant

coronary

artery

etiology.

FOLLOW-UP
Our patient received hydroxychloroquine and lowdose glucocorticoids as per our institutional treatment protocol; however, it is important to note
that currently there are no proven data for efﬁcacy
of this regimen for COVID-19. We also treated our
patient with colchicine, given the elevated inﬂammatory makers. The patient was continued on
guideline-directed medical therapy for nonischemic
cardiomyopathy
tensin

including

receptor

blockers,

beta-blockers,
and

angio-

spironolactone.

Repeat TTE prior to discharge demonstrated stable
ejection

fraction

and

resolution

of

pericardial

effusion.

CONCLUSIONS

cascade post–myocardial infarction (7,8).
After pericardiocentesis, our patient developed TTC

We

report

a

rare

presentation

of

COVID-19

as evident by TTE, ECG ﬁndings, and cTnI elevation.

infection complicated by a large symptomatic hem-

TTC is a stress-induced cardiomyopathy characterized

orrhagic pericardial effusion and development of

by transient apical ballooning with regional wall mo-

TTC.

tion abnormalities that occur in association with
identiﬁable emotional or physical stressors including

ADDRESS FOR CORRESPONDENCE: Dr. Mohammed

infections (9). The Mayo Clinic proposed the following

F. Dabbagh, Heart and Vascular Institute, Henry Ford

diagnostic criteria for diagnosis of TTC: transient

Hospital, 2799 West Grand Boulevard, K14, Detroit,

segmental

Michigan

left

ventricular

systolic

dysfunction,

absence of obstructive coronary artery disease, new

48202.

E-mail:

Twitter: @FerrasDabbagh1.
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